Table 1.

Examples of drugs approved for sale subsequently withdrawn from the market due to liver and cardiac toxicity

Drug	Year	Reason for withdrawal
Terfenadine (Seldane)	1998	Risk of cardiac arrhythmias
Alpidem (Ananxyl)	1999	Rare serious hepatotoxicity
Grepafloxacin (Raxar)	1999	Prolonged QT interval
Troglitazone (Rezulin)	2000	Risk of hepatotoxicity
Trovafloxacin (Trovan)	2001	Risk of liver failure
Rofecoxib (Vioxx)	2004	Risk of myocardial infarction
Rosiglitazone (Avandia)	2010	Withdrawn in Europe because of increased risk of myocardial infarction and death. This drug continues to be available in the USA